News

The latest from Velocity Clinical Research

Velocity Joins the IQVIA Connected Research Community in Europe

February 6, 2024

Velocity is proud to be a part of IQVIA’s Prime and Partner Site Programme. IQVIA have created a joint innovation group with representatives from their elite network of Prime and Super Partner sites across Europe, known as the “IQVIA Connected Research Community”. The purpose is … Read more

Video: Community Engagement

February 3, 2024

To bring equitable products to market, clinical trials need proportionate representation. Reaching the right patients must be prioritized at the site level, where clinical research is most visible in communities. Therefore, Velocity is heavily invested in leveraging the power of local influence to drive … Read more

Julio Rosenstock, MD, FACE, Co-Authored an Article Published in Cardiovascular Diabetology

February 2, 2024

Julio Rosenstock, MD, FACE, is an author of an article published yesterday in Cardiovascular Diabetology. Using baseline characteristics of study participants from an ongoing trial, researchers identified clinical characteristics of individuals with type 2 diabetes and features of stage B heart failure that may help … Read more

Video: Environmental Governance

January 19, 2024

As Nicholas Campbell explains, good business can also be good for the environment. As Velocity improves lives by accelerating the development of new therapies, we can also build a healthier tomorrow by conducting trials in a sustainable way. How can Velocity deliver more efficient trials? Enhanced … Read more

Julio Rosenstock, MD, FACE, Lead Author Published in OUP Endocrine Reviews Article

January 16, 2024

Julio Rosenstock, MD, FACE, is the lead author of an article published today in the Oxford University Press’ Endocrine Reviews Journal. Reviewing data from Phase 2 clinical trials for basal insulins icodec and efsitora, as well as the Phase 3 icodec program, the article indicates that … Read more

Paul Evans, Nadege Gunn Featured in ACRP Trend Prediction Article

January 11, 2024

Paul Evans, President and CEO and Nadege Gunn, MD, CPI, Medical Director and Senior Scientific Advisor for Velocity are highlighted in a recent article by the ACRP, The Year Ahead in Trends, Challenges, and Opportunities for Clinical Trial Sites. In the article, Dr. Gunn … Read more

Video: Demand and Delivery

January 9, 2024

Watch Christy Godwin and Laura Falcone discuss Velocity’s unique ‘Demand and Delivery’ approach. Christy and Laura work in unison to ensure full alignment among what Sponsors and CROs demand, and the quality, performance, and patient experiences Velocity delivers. In this video, they delve into: … Read more

Velocity Transforms Patient Experience and Recruitment With VISION Technology Platform

January 9, 2024

Velocity Clinical Research, the leading multi-specialty clinical sites business, has launched its VISION technology platform to transform the way patients access and participate in clinical trials.  Velocity’s VISION technology unifies patient experience and recruitment capabilities across nearly 100 locations globally. The AI-driven platform includes … Read more

Video: Scale for a Purpose

January 3, 2024

A staggering 80% of clinical trials are delayed or shut down due to enrollment challenges, with half of those delays occurring at the site level. Two-thirds of principal investigators leave research after conducting a single trial. It’s time for a change. Watch Paul Evans, … Read more

Velocity Expands to 17 Sites in Europe

January 3, 2024

Velocity Clinical Research, the leading multi-specialty clinical sites organization, today announces its further expansion in Europe, adding five sites in Poland after acquiring multi-site network KO-MED Centra Kliniczne and two in Germany, having acquired The Pulmonary Research Institute at the LungenClinic Grosshansdorf and KLB … Read more

Velocity Supported Clinical Trials That Led to 12 Product Approvals in 2023

December 27, 2023

Velocity has made an incredible impact over the past year! Our sites conducted clinical trials that supported 12 U.S. product approvals in 2023, contributing to the betterment of global health. To date, Velocity has contributed to research programs for over 50 product approvals. From … Read more

Removing Language as a Barrier for Clinical Trial Participants

December 19, 2023

Velocity Clinical Research is committed to inclusivity and ensuring that everyone, regardless of their nationality or spoken language, can participate in groundbreaking clinical research studies. Language should never be a barrier to advancing medicine, and so, in collaboration with Boostlingo, we offer live phone … Read more

Learn more about Velocity's capabilities

Whether you’re ready to conduct a single-site study or a complex, high-volume trial, Velocity will ensure you have the right investigators, clinical staff, and patients for your research program.

Join a remarkable team doing remarkable work

Velocity careers offer competitive pay and benefits, and reward high performance with excellent opportunities.

Whether you're an industry veteran or are looking to take your first step into clinical research, we invite you to apply at Velocity.

Quality. Continuity. Velocity.